1 |
Kim BK, Chu MK, Lee TG, et al. Prevalence and impact of migraine and tension-type headache in Korea. J Clin Neurol 2012;8:204-11.
DOI
|
2 |
Kim SM, Ko YH, Yoon S, et al. Evidence-based clinical guideline for diagnosis and management of headache in Korea. Psychiatry Investig 2019;16(3):199-205.
DOI
|
3 |
Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012;2012(2):CD008615.
|
4 |
Antonaci F, Ghiotto N, Wu S, et al. Recent advances in migraine therapy. SpringerPlus 2016;5;637.
DOI
|
5 |
Chu MK. Diagnosis and treatment of migraine. Korean J Fam Med 2006;27:425-35.
|
6 |
Chung CS. Drug therapy for migraine. J Korean Med Assoc 2007;50(10):917-23.
DOI
|
7 |
Diener HC, Charles A, Goadsby PJ, et al. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol 2015;14:1010-22.
DOI
|
8 |
Chan K, MaassenVanDenBrink A. Glutamate receptor antagonists in the management of migraine. Drugs 2014;74:1165-76.
DOI
|
9 |
Hoffmann J and Charles A. Glutamate and its receptors as therapeutic targets for migraine. Neurotherapeutics 2018;15:361-70.
DOI
|
10 |
Andreou AP and Goadsby PJ. Therapeutic potential of novel glutamate receptor antagonists in migraine. Expert Opin Investig Drugs 2009;18(6):789-803.
DOI
|
11 |
Ferrari A, Rustichelli C, Baraldi C. Glutamate receptor antagonists with the potential for migraine treatment. Expert Opin Investig Drugs 2017; 06(12):1321-30.
|
12 |
Monteith D, Jones RS, Verfaille SJ. Phase 2 trial of LY2300559 for treatment of acute migraine headaches. Cephalalgia 2013;33(11):981.
|
13 |
Sang CN, Ramadan NM, Wallihan RG, et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004;24:596-602.
DOI
|
14 |
Gomez-Mancilla B, Brand R, Jurgens TP, et al. Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia 2014; 34(2):103-13.
DOI
|
15 |
Waung MW, Akerman S, Wakefield M, et al. Metabotropic glutamate receptor 5: a target for migraine therapy. Ann Clin Transl Neurol 2016;3(8):560-71.
DOI
|
16 |
Lupi C, Benemei S, Guerzoni S, et al. Pharmacokinetics and pharmacodynamics of new acute treatments for migraine. Expert Opin Drug Metab Toxicol 2019;15(3):189-98.
DOI
|
17 |
Headache Classification Committee of the International Headache Society. The international classification of headache disorders (second edition). Cephalalgia 2004;24(Suppl 1):1-160.
|
18 |
Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia 2019;39(6):687-710.
DOI
|
19 |
Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia 2012;32(1):6-38.
DOI
|
20 |
Kang H. Statistical considerations in meta-analysis, Hanyang Med Rev 2015;35:23-32.
DOI
|
21 |
Kim SY, Park JE, Seo HJ, et al. NECA's guidance for undertaking systematic reviews and meta-analyses for intervention. Seoul: National Evidence-based Healthcare Collaborating Agengy 2011;129-99.
|